A detailed history of Smith Anglin Financial, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Smith Anglin Financial, LLC holds 3,777 shares of ABBV stock, worth $679,860. This represents 0.07% of its overall portfolio holdings.

Number of Shares
3,777
Previous 3,540 6.69%
Holding current value
$679,860
Previous $607,000 22.73%
% of portfolio
0.07%
Previous 0.06%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 07, 2024

BUY
$163.84 - $199.33 $38,830 - $47,241
237 Added 6.69%
3,777 $745,000
Q2 2024

Jul 10, 2024

BUY
$154.79 - $180.76 $928 - $1,084
6 Added 0.17%
3,540 $607,000
Q1 2024

Apr 24, 2024

BUY
$159.82 - $182.1 $40,434 - $46,071
253 Added 7.71%
3,534 $643,000
Q4 2023

Jan 17, 2024

BUY
$137.6 - $154.97 $7,705 - $8,678
56 Added 1.74%
3,281 $508,000
Q3 2023

Oct 11, 2023

BUY
$133.59 - $154.65 $3,874 - $4,484
29 Added 0.91%
3,225 $480,000
Q2 2023

Jul 10, 2023

BUY
$132.51 - $164.9 $4,637 - $5,771
35 Added 1.11%
3,196 $430,000
Q1 2023

Apr 11, 2023

BUY
$144.61 - $166.54 $17,063 - $19,651
118 Added 3.88%
3,161 $503,000
Q4 2022

Feb 14, 2023

SELL
$138.31 - $165.87 $10,096 - $12,108
-73 Reduced 2.34%
3,043 $492,000
Q3 2022

Oct 24, 2022

BUY
$134.21 - $153.93 $4,026 - $4,617
30 Added 0.97%
3,116 $418,000
Q2 2022

Jul 25, 2022

SELL
$137.62 - $174.96 $29,175 - $37,091
-212 Reduced 6.43%
3,086 $473,000
Q1 2022

May 16, 2022

SELL
$131.98 - $163.75 $791 - $982
-6 Reduced 0.18%
3,298 $535,000
Q4 2021

Jan 31, 2022

BUY
$107.43 - $135.93 $23,419 - $29,632
218 Added 7.06%
3,304 $447,000
Q3 2021

Oct 20, 2021

SELL
$106.4 - $120.78 $26,919 - $30,557
-253 Reduced 7.58%
3,086 $333,000
Q2 2021

Aug 10, 2021

BUY
$105.21 - $117.21 $4,524 - $5,040
43 Added 1.3%
3,339 $376,000
Q1 2021

Jul 08, 2021

SELL
$102.3 - $112.62 $4,501 - $4,955
-44 Reduced 1.32%
3,296 $357,000
Q4 2020

Jul 08, 2021

BUY
$80.49 - $108.67 $268,836 - $362,957
3,340 New
3,340 $358,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Smith Anglin Financial, LLC Portfolio

Follow Smith Anglin Financial, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Smith Anglin Financial, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Smith Anglin Financial, LLC with notifications on news.